Annual Report 2025

Change report

Consolidated statement of cash flows

Consolidated statement of cash flows

January 1 to December 31, € in millions

 

Note

 

2025

 

2024 restated1

 

2024 previous

Operating activities

 

 

 

 

 

 

 

 

Operating activities – continuing operations

 

 

 

 

 

 

 

 

Net income from continuing operations

 

 

 

1,606

 

1,152

 

867

Adjustments to reconcile net income from continuing operations to cash and cash equivalents provided by operating activities

 

 

 

 

 

 

 

 

Depreciation and amortization

 

18, 19, 20, 21, 34

 

1,120

 

1,239

 

1,204

Change in deferred taxes

 

11

 

-23

 

43

 

33

Gain on sale of fixed assets and of investments and divestitures

 

2

 

-166

 

-1

 

-1

Gain from the investments accounted for
using the equity method

 

 

 

-198

 

-38

 

-38

Changes in assets and liabilities, net of amounts
from businesses acquired or disposed of

 

 

 

 

 

 

 

 

Trade accounts and other receivables

 

16

 

-220

 

43

 

21

Inventories

 

17

 

-210

 

-67

 

-55

Other current and non-current assets

 

18, 19

 

-149

 

95

 

229

Accounts receivable from / payable to related parties

 

 

 

15

 

-90

 

-54

Trade accounts payable, provisions and
other short-term and long-term liabilities

 

23, 24, 25

 

756

 

51

 

146

Income tax liabilities

 

 

 

75

 

47

 

49

Net cash provided by operating activities – continuing operations

 

 

 

2,606

 

2,474

 

2,401

Net cash used in/provided by operating activities – discontinued operations

 

 

 

-32

 

-27

 

46

Net cash provided by operating activities

 

 

 

2,574

 

2,447

 

2,447

Investing activities

 

 

 

 

 

 

 

 

Investing activities – continuing operations

 

 

 

 

 

 

 

 

Purchases of property, plant and equipment and capitalized development costs

 

20

 

-1,105

 

-980

 

-923

Proceeds from subsidies to finance hospital-related property, plant and equipment

 

 

 

119

 

57

 

Proceeds from sales of property, plant and equipment

 

 

 

173

 

7

 

7

Acquisitions and investments
and purchases of intangible assets

 

2, 37

 

-392

 

-80

 

-80

Proceeds from sale of investments and divestitures

 

2, 37

 

620

 

269

 

394

Dividends received from Fresenius Medical Care

 

 

 

121

 

112

 

112

Net cash used in investing activities – continuing operations

 

 

 

-464

 

-615

 

-490

Net cash used in/provided by investing activities – discontinued operations

 

 

 

-351

 

105

 

-20

Net cash used in investing activities

 

 

 

-815

 

-510

 

-510

Financing activities

 

 

 

 

 

 

 

 

Financing activities – continuing operations

 

 

 

 

 

 

 

 

Proceeds from short-term debt

 

26

 

91

 

52

 

52

Repayments of short-term debt

 

26

 

-103

 

-496

 

-496

Proceeds from long-term debt

 

26

 

411

 

10

 

10

Repayments of long-term debt

 

26

 

-1,318

 

-602

 

-546

Repayments of lease liabilities

 

34

 

-173

 

-180

 

-181

Proceeds from the issuance of bonds

 

27

 

1,000

 

240

 

240

Repayments of liabilities from bonds

 

27

 

-2,250

 

-700

 

-700

Proceeds from the issuance of the exchangeable bond

 

28

 

609

 

 

Repayments of convertible bonds

 

 

 

 

-500

 

-500

Dividends paid

 

 

 

-684

 

 

Change in noncontrolling interests, net

 

30

 

-6

 

-13

 

-13

Net cash used in financing activities – continuing operations

 

 

 

-2,423

 

-2,189

 

-2,134

Net cash provided by/used in financing activities – discontinued operations

 

 

 

 

6

 

-49

Net cash used in financing activities

 

 

 

-2,423

 

-2,183

 

-2,183

Effect of exchange rate changes on cash and cash equivalents

 

 

 

-33

 

-2

 

-2

Net decrease in cash and cash equivalents

 

 

 

-697

 

-248

 

-248

Cash and cash equivalents at the beginning of the reporting period

 

15

 

2,282

 

2,562

 

2,562

less cash and cash equivalents at the end of the reporting period
shown under "assets held for sale"

 

 

 

 

32

 

32

Cash and cash equivalents at the end of the reporting period

 

15

 

1,585

 

2,282

 

2,282

1

Prior-year figures have been adjusted due to the gradual exit from Fresenius Vamed and a change in classification (see note 1. III. c, Classifications).

Additional information on payments that are included in net cash provided by operating activities – continuing operations

Consolidated statement of cash flows – Additional Information

January 1 to December 31, € in millions

 

Note

 

2025

 

2024 restated1

 

2024 previous

Received interest

 

 

 

68

 

71

 

72

Paid interest

 

 

 

-368

 

-415

 

-415

Income taxes paid

 

 

 

-463

 

-430

 

-430

1

Prior-year figures have been adjusted due to the gradual exit from Fresenius Vamed (see note 1. III. c, Classifications).

The following notes are an integral part of the consolidated financial statements.